HPLC Analysis of Phosphorylated Peptides on the Alliance™ iS Bio System with MaxPeak™ High Performance Surface (HPS) Technology - A System Designed for Bioseparations

Importance of the topic

Phosphorylated peptides are critical analytes in biopharmaceutical characterization and quality control because phosphorylation is a common post‑translational modification that affects biological activity. Under typical reversed‑phase HPLC conditions, phosphate groups can interact non‑specifically with metal surfaces (Lewis acid–base interactions), causing peak tailing, reduced recovery, and poor area precision. Reducing nonspecific adsorption (NSA) and ensuring precise gradient delivery are therefore essential for reliable peptide mapping in regulated laboratories and process control workflows.

Objectives and study overview

The application note compares the Alliance iS Bio HPLC System (incorporating MaxPeak High Performance Surface, HPS, technology) with a legacy stainless‑steel HPLC system and a second bio‑inert HPLC system. Goals were to evaluate: retention time precision, area precision, peak tailing, and baseline noise for a set of phosphorylated peptides (three singly phosphorylated and one doubly phosphorylated), and to determine whether MaxPeak HPS and the Alliance iS Bio quaternary pump improve performance for peptide mapping under long, shallow gradients.

Methodology

• Analyte: Waters MassPREP Phosphopeptide Standard (yeast enolase-derived), containing four phosphorylated peptides (t18p, t19p, t43p singly phosphorylated; t43pp doubly phosphorylated). Replicates: six injections per system.
• Sample handling: Standards reconstituted in Mobile Phase A and transferred to QuanRecovery MaxPeak HPS polypropylene vials to limit surface binding.
• Column and mobile phases: XSelect Premier Peptide CSH C18 (4.6 × 100 mm, 2.5 μm, 130 Å). Mobile phase A = 0.1% TFA in water; B = 0.1% TFA in acetonitrile.
• Chromatographic conditions: flow 0.500 mL/min; injection 25 μL; sample temp 5 °C; column 60 °C; detection 214 nm; data rate 5 Hz. Systems compared: Alliance iS Bio (MaxPeak HPS), Bio‑inert System X, and a legacy stainless‑steel system. All systems are quaternary but differ in dwell volume, stroke volume, and mixer configuration.
• Data system: Empower 3.8.0.1 for acquisition and processing.

Used instrumentation

• Alliance iS Bio HPLC System with MaxPeak High Performance Surface (HPS) technology (Waters).
• Bio‑inert HPLC System X (unnamed manufacturer/system in study).
• Legacy stainless‑steel quaternary HPLC system.
• XSelect Premier Peptide CSH C18 column (4.6 × 100 mm, 2.5 μm, 130 Å).
• QuanRecovery MaxPeak HPS polypropylene vials for sample storage.
• Empower chromatography data software.

Main results and discussion

• Baseline noise: The Alliance iS Bio system produced the lowest USP noise (average 3.9 × 10⁻⁵ μAU) compared with Bio‑inert System X (1.8 × 10⁻⁴ μAU) and the stainless‑steel system (1.7 × 10⁻⁴ μAU). Contributing factors include Alliance iS Bio’s lower pump stroke volume and presence of an in‑line mixer, which reduce baseline ripple for shallow TFA gradients.
• Retention time precision: All systems yielded RT standard deviations <0.02 min. Alliance iS Bio showed the best repeatability with a maximum RT SD of 0.003 min; System X and the stainless system had maxima of 0.010 and 0.016 min, respectively. Improved pump performance supports precise gradient composition over extended shallow gradients used in peptide mapping.
• Peak tailing (USP tailing): For singly phosphorylated peptides (t19p, t43p) tailing was similar across systems. For the doubly phosphorylated peptide t43pp—most prone to NSA—the stainless‑steel system exhibited significantly worse and more variable tailing. Bio‑inert systems (including MaxPeak HPS) mitigated this effect.
• Area precision and recovery: For the three singly phosphorylated peptides, area %RSDs were <1.2% across systems; Alliance iS Bio achieved <0.4% RSD. For the doubly phosphorylated t43pp, both bio‑inert systems provided similar height and area with area %RSDs under 2.5%. The stainless‑steel system produced substantially reduced peak height/area (≈ one‑third of bio‑inert response) and elevated area %RSD (~7.9%), consistent with analyte loss due to NSA.
• Overall interpretation: The data indicate that MaxPeak HPS and a carefully engineered flow path reduce NSA of phosphorylated peptides, improving sensitivity, precision, and peak shape. Additionally, the Alliance iS Bio quaternary pump design supports highly repeatable gradient delivery required for long, shallow peptide mapping gradients.

Benefits and practical applications

• Improved recovery and precision for metal‑sensitive peptides (notably multiply phosphorylated species) enhances confidence in peptide mapping, impurity profiling, and CQA monitoring in regulated workflows.
• Lower baseline noise and more stable gradients facilitate better quantitation at low UV wavelengths commonly used for peptides with TFA mobile phases.
• Reduced need for repeated passivation or other time‑consuming NSA mitigation strategies, leading to more robust day‑to‑day operation and less method maintenance.
• Applicability extends to LC–MS workflows where maximizing recovery of phosphopeptides is critical for identification and quantitation.

Future trends and applications

• Continued adoption of bio‑inert surface technologies across UHPLC/HPLC platforms to minimize NSA for a broader range of post‑translationally modified peptides and other labile biomolecules.
• Integration of optimized low‑dispersion flow paths and low‑stroke pumps to improve gradient fidelity for long, shallow gradients used in complex separations.
• Expansion of standardized reagent and consumable ecosystems (vials, fittings, tubing) treated with high‑performance surfaces to limit sample loss across the analytical chain.
• Combination of bio‑inert LC systems with high‑sensitivity MS to enhance phosphoproteomics workflows and trace‑level CQA monitoring in biopharma development.

Conclusion

The Alliance iS Bio HPLC System with MaxPeak HPS technology demonstrated superior performance for analysis of phosphorylated peptides compared with a legacy stainless‑steel system and performed comparably or better than an alternative bio‑inert system. Key advantages included reduced NSA (improved recovery and peak shape for the doubly phosphorylated peptide), lower baseline noise, and highly repeatable retention times attributable to pump and flow path design. These improvements support more reliable peptide mapping and routine monitoring of phosphorylation‑related CQAs in regulated laboratories.

References

1. Walter TH, Trudeau M, Simeone J, Rainville P, Patel AV, Lauber M, Kellett J, DeLano M, Brennan K, Boissel C, Birdsall RE, Berthelette K. Low Adsorption UPLC Systems and Columns Based on MaxPeak High Performance Surfaces: The Acquity Premier Solution. Waters White Paper. 2021.
2. Koshel BM, Simeone J, Dao D, Nguyen JM, Rzewuski SC, Lauber M, Birdsall RE, Yu YQ. Bypassing LC System Passivation Requirements Using Acquity Premier with MaxPeak HPS Technology for the Recovery of a Phosphorylated Peptide. Waters Application Note. 2020.
3. Hughes C, Gethings LA, Plumb RS. Maximizing Phosphopeptide Recovery in LC‑MS Studies with MaxPeak High Performance Surfaces Technology. Waters Application Note. 2020.
4. Martin K, Gauthier L, Hong P. Improved Sensitivity for Trifluoroacetic Acid Gradients on the Alliance iS HPLC Systems. Waters Application Note. 2024.
5. Alliance iS HPLC System Specification Sheet. Waters. 2025.